EyePoint Pharmaceuticals (EYPT) Tops Q3 EPS by 2c

EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q3 EPS of ($0.54), $0.02 better than the analyst estimate of ($0.56). Revenue for the quarter came in at $10.5 million versus the consensus estimate of $10.06 million.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.

You May Also Be Interested In

• Nucor projects Q3 2026 earnings above prior year, below estimates
• Rexford Industrial closes $1.2B portfolio sale to EQT Real Estate
• Allied Gold connects Kurmuk mine to Ethiopia's grid, feeds first ore